Simcyp Limited releases new version of the Simcyp Population-based ADME Simulator

Sheffield, UK, 2nd April 2008 – Simcyp Limited, the leader in predictive pharmacokinetics, has released Version 8.0 of the *'Simcyp Population-based ADME Simulator',* an advanced platform for the modelling and simulation of drug absorption, distribution, metabolism and elimination (ADME) in virtual populations. The new features incorporated into Version 8.0 were determined in consultation with the Simcyp Consortium, which currently includes nine out of the top ten pharmaceutical companies worldwide.

The Simcyp Simulator allows preclinical data to be used to maximum advantage in drug development; informing the design of human studies and allowing 'what if' questions to be explored in the safety of a computer.

Executive Director of Simcyp, Dr Steve Toon said: *"It is estimated that in the near future up to 15% of drug development budgets will be spent on modelling and simulation, and the benefits to the industry are rapidly becoming apparent. For example, complex multiple drug-drug interactions involving various enzyme inhibition or induction mechanisms can now be simulated using the Simcyp platform as a prelude to undertaking a clinical study. This not only helps optimise the study design but minimises the risk to the clinical study subjects."*

Simcyp simulations incorporate known population variability, producing relevant 'real world' predictions which are more informative than simulations performed in a single 'average' reference man. In addition to modelling the fate of drugs in Caucasian and Japanese populations, the Simcyp Simulator can predict drug-fate in patients with liver cirrhosis, renal impairment and obesity. Furthermore, a 'healthy volunteer' library within the platform allows drug companies to carry out virtual Phase I studies, helping to improve the design of real studies in humans.

Commenting on the new release, Professor Amin Rostami-Hodjegan, Director of Research and Development at Simcyp said: *"The recent enhancements to the Simcyp Simulator will prove particularly useful to scientists working in pharmaceutics, as the Simcyp absorption model can now accommodate a variety of different drug formulations. Many factors which affect the subsequent bioavailability of a drug, including food intake, variability in pH and concentration-dependent effects of efflux transporters in the gut, can now also be simulated using Simcyp."*

– Ends –

About Simcyp

Simcyp is a research-based company providing a modelling and simulation platform for predicting the fate of drugs in virtual populations. From this, individual patients likely to be at extreme risk from adverse drug reaction can be identified, and unnecessary exposure to human volunteers and animals

can be minimised. The clinical limitations of candidate compounds, including potential drug-drug interactions, can be assessed and managed prior to human studies, allowing better focus of drug development resources.

Scientific development at Simcyp is guided by a Consortium of leading pharmaceutical companies, ensuring that Simcyp's products and services continue to meet, and exceed, industry needs. Simcyp maintains strong academic links and conducts internationally recognised research and development. The Company also offers consultancy services, and runs international education programmes

For further information, please visit our website at www.simcyp.com.

Please contact:

College Hill:
Tristan Jervis, Tony Stephenson, Claire Mosley
Phone: +44 20 7457 2020
Email: simcyp@collegehill.com